FARM IP, ENTER WIPO

Developing countries will now have to battle IP issues related to new agricultural technologies at WIPO instead of WTO

Brickbats for compulsory licences

US criticises India and BRIC group for strengthening provisions on life-saving medicines

How to save $25 billion and more on drug costs

Patent settlements bring cheaper generics to market early and cut healthcare spending

Spy versus spy and high tech gizmos

From secure manhole covers to Internet tracking systems, NSA has an arsenal of patents

Strong medicine for weak drug patents

Revocation of Pfizer, Roche patents for lacking inventive step signals healthy trend

Best way to check arsenic residues in rice

Biodiversity—India’s other scandal

CAG slams the national biodiversity authority for allowing questionable patents

Japanese biopiracy of our Ballia barley

Japan’s Sapporo brewery patents Indian barley gene without giving benefit to farmers

Getting the drug equation right

Sonal Matharu reports how fights over counterfeit drugs and low-quality drugs is suppressing the larger issue of drug safety

Public Funded R&D Bill may benefit the private sector

Free trade will bind India

Rotten tomato for Monsanto

US biotech giant's claim on a natural tomato is its latest patent to be revoked by Europe after soy and wheat

The fine line for judges

Judges have recused themselves in a number of cases but there are no clear guidelines on what constitutes conflict of interest  

Legislation for a few

Benefits of the Act that encourages conservation of plants reach few farmers

Foss time in India

Microsoft is the most familiar term in the proprietary software industry. The company's penetration in people's minds is so deep that it is often …

MONEYMAKERS

Maths of Gilead's hepatitis C drug

Why US firm's super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price

Cipla's bitter pill for MNCs

Several eyebrows have been raised over the Cipla offer to supply anti- aids drugs at one-third the current price to developing countries like …

Obama takes first dip

The US becomes the first to join a global patents pool to make AIDS drugs cheaper but health workers are sceptical of the initiative

Access, yes. Sharing, no

The access and benefit-sharing protocol on biodiversity may do little to deter multinationals from grabbing the planet’s resources

ABCDE of Obama’s sales pitch

Evergreen Novartis

The Swiss pharma giant’s challenge to India’s patent law, now in the Supreme Court, may help define drug efficacy

The Kani learning

How benefit-sharing between a research institute and the Kani tribe went awry

Novartis exposes India's weak patent laws. Will generics be kicked out?

Rajasthan opens farm gates

State ties up with Monsanto, other biotech giants to restructure agriculture